Co-development and licensing deals set to spur on diabetes market growth
The development of new diabetes medications are now more-commonly the result of deals between companies, a new study by pharmaceutical intelligence expert GBI Research has revealed.
The report found that, while major companies account for significant shares of the market, smaller firms are more able to compete using new strategies involving mergers, acquisitions, licensing deals and co-operation within the market, which is expected to boost product development until at least 2017.
Over 60 million people around the world suffer from diabetes, with the diabetic population currently rising further in key markets such as the USA, the UK and Germany, increasing the profitability of popular diabetes therapeutics. While the diabetes market is presently dominated by insulins, demand remains for products that are easier for patients to administer, and this growth potential is driving deals activity in the industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze